- Home
- GMAB vs SUZ Comparison
GMAB vs SUZ Comparison
Compare GMAB & SUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- SUZ
- Stock Information
- Founded
- GMAB 1999
- SUZ 1924
- Country
- GMAB Denmark
- SUZ Brazil
- Employees
- GMAB N/A
- SUZ N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- SUZ Paper
- Sector
- GMAB Health Care
- SUZ Basic Materials
- Exchange
- GMAB Nasdaq
- SUZ Nasdaq
- Market Cap
- GMAB 15.0B
- SUZ 12.8B
- IPO Year
- GMAB N/A
- SUZ N/A
- Fundamental
- Price
- GMAB $20.31
- SUZ $9.77
- Analyst Decision
- GMAB Buy
- SUZ
- Analyst Count
- GMAB 8
- SUZ 0
- Target Price
- GMAB $43.00
- SUZ N/A
- AVG Volume (30 Days)
- GMAB 1.2M
- SUZ 2.3M
- Earning Date
- GMAB 02-12-2025
- SUZ 10-24-2024
- Dividend Yield
- GMAB N/A
- SUZ 2.45%
- EPS Growth
- GMAB 14.35
- SUZ N/A
- EPS
- GMAB 10.80
- SUZ 0.60
- Revenue
- GMAB $2,967,926,227.00
- SUZ $8,006,653,403.00
- Revenue This Year
- GMAB $30.31
- SUZ $14.70
- Revenue Next Year
- GMAB $16.49
- SUZ $10.62
- P/E Ratio
- GMAB $18.44
- SUZ $15.83
- Revenue Growth
- GMAB 17.75
- SUZ N/A
- 52 Week Low
- GMAB $19.85
- SUZ $8.78
- 52 Week High
- GMAB $32.88
- SUZ $12.98
- Technical
- Relative Strength Index (RSI)
- GMAB 36.70
- SUZ 35.26
- Support Level
- GMAB $19.99
- SUZ $9.78
- Resistance Level
- GMAB $21.03
- SUZ $10.65
- Average True Range (ATR)
- GMAB 0.38
- SUZ 0.21
- MACD
- GMAB -0.07
- SUZ -0.11
- Stochastic Oscillator
- GMAB 18.55
- SUZ 3.57
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.